Northwestern Mutual Wealth Management
CLDI icon

Northwestern Mutual Wealth Management’s Calidi Biotherapeutics CLDI Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28
Closed -$33 – 4184
2025
Q4 		$33 Buy
+28
New +$41 ﹤0.01% 3927

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Northwestern Mutual Wealth Management's CLDI Position: Q1 2026 in Review

Northwestern Mutual Wealth Management sold out of Calidi Biotherapeutics (CLDI) in Q1 2026, closing a stake of 28 shares — an estimated $33 sold.

Northwestern Mutual Wealth Management first reported a position in CLDI in Q4 2025 and held it in 1 quarter. The position peaked at $33 in Q4 2025. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • Northwestern Mutual Wealth Management reported no remaining Calidi Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Northwestern Mutual Wealth Management sold 28 Calidi Biotherapeutics shares in Q1 2026, an estimated $33.
  • Northwestern Mutual Wealth Management first reported a position in Calidi Biotherapeutics in Q4 2025 and held it in 1 quarter.
  • Northwestern Mutual Wealth Management's Calidi Biotherapeutics position peaked at $33 in Q4 2025.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.